[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"McMaster University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":729},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,98,0,25,[9,50,80,112,142,169,192,212,236,266,295,324,350,377,410,440,471,500,536,577,605,633,652,682,704],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100615124","phase-4-a-2x2-factorial-randomized-open-label-trial-to-evaluate-neuromodulators-and-cough-control-therapy-in-patients-with-refractory-or-unexplained-chronic-cough-100615124",false,"NCT07288528","A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough","A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough (FORTITUDE)","FORTITUDE","Inclusion Criteria:\n\n1. Adults (≥18 years old) with either:\n2. Refractory chronic cough (RCC), defined as having one or more identifiable causes of cough (asthma, allergic rhinitis, and\u002For GERD), but with previous trials of treatment targeting the underlying condition leading to no cough resolution; OR\n3. Unexplained chronic cough (UCC), defined as having a cough lasting \\>8 weeks with (i) a normal chest X-ray\u002FCT in the last 5 years and since the onset of chronic cough; (ii) FEV1 and FVC ≥80% predicted or \\>lower limit of normal (LLN); (iii) FEV1\u002FFVC ≥0.7 or \\>LLN; (iv) no evidence of asthma; and (vi) no regular symptoms of nasal\u002Freflux disease.\n\nExclusion Criteria:\n\n1. Those who, in the opinion of the investigator, have previously tried low-dose morphine, pregabalin, and\u002For CCT with full intervention fidelity for the treatment of RCC\u002FUCC;\n2. Are currently taking morphine or pregabalin for the treatment of any indication (i.e., RCC\u002FUCC or chronic pain);\\*\n3. Are currently taking other centrally-acting medication (i.e., gabapentin, amitriptyline, dextromethorphan) for the treatment of any indication (i.e., RCC\u002FUCC, seizures, or depression);\\*\n4. Have a history of opioid or substance abuse that, in the opinion of the investigator, may interfere with the conduct of the study;\n5. Are a current smoker, or ex-smoker with a \\>20 pack-year history who have abstained from smoking for \\\u003C6 months;\n6. Have cough due to angiotensin-converting enzyme inhibitor use;\n7. Have symptoms of an upper respiratory infection within the last month that have not resolved;\n8. Had an asthma exacerbation within the last month that requires an increase or start of an oral corticosteroid;\n9. Have other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, interstitial lung disease, or severe bronchiectasis;\n10. Have language, memory, cognitive, or psychiatric issues that may prevent optimal participation;\n11. Have creatinine clearance \\\u003C15 mL\u002Fmin, including individuals with end-stage renal disease who require hemodialysis or peritoneal dialysis;\n12. Have any other condition that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant;\n13. Have participated in another clinical trial of an investigational medicinal product within 30 days;\n14. Pregnant or breastfeeding; or\n15. Females of child-bearing potential who:\n\n    1. Do not agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months.\n    2. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening.\n    3. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening.\n\n       * Participants taking any of the above medications at baseline will only be eligible if they are willing and medically able to safely discontinue them at least 2 weeks prior to the first study visit. Eligibility will be confirmed by the local study investigator prior to enrolment.","ALL","18 Years",{"count":21,"type":22},124,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The FORTITUDE trial will provide head-to-head evidence on the benefits and harms of two commonly prescribed neuromodulators (low-dose morphine and pregabalin), the effectiveness of a virtual cough control therapy, exploratory assessment of potential synergy in combining these interventions, and the long-term outcomes of these treatments in patients with refractory or unexplained chronic cough.",[28,29,30,31,32],"Cough","Refractory Chronic Cough","Unexplained Chronic Cough","Cough Hypersensitivity Syndrome","Chronic Cough",[28,32,34,35,36,29,30],"Morphine","Pregabalin","Non-Pharmacologic Therapy","NOT_YET_RECRUITING","2026-08-17",{"date":40,"type":41},"2026-08-19","ACTUAL",{"date":43,"type":22},"2026-09-30",{"date":45,"type":22},"2029-10-01",{"name":47,"class":48},"McMaster University","OTHER",5,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":57,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100651203","group-cbt-for-paternal-perinatal-depression-rct-100651203","NCT07758036","Group CBT for Paternal Perinatal Depression","Group Cognitive Behavioural Therapy for Paternal Perinatal Depression: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Non-birthing individuals identifying as fathers-to-be (i.e., have a pregnant partner) or fathers who have an infant \\\u003C18 months at recruitment\n* Fluent in written\u002Fspoken English\n* Have an EPDS score ≥9\n* Live in Ontario\n\nExclusion Criteria:\n\n* Free of bipolar, psychotic, borderline personality and current substance use disorders","MALE",{"count":59,"type":22},112,[61],"NA","The purpose of the proposed study is to determine the effectiveness of an online, 9-week group cognitive behavioural therapy (CBT) intervention for paternal perinatal depression (PND) in fathers and fathers-to-be. Fathers or fathers-to-be living in Ontario, Canada who have depression symptoms while their partner has been pregnant and\u002For during the first 18 months of their child's life will be assigned with a 50\u002F50 chance (like flipping a coin) to receive online group CBT in addition to usual care, or to receive usual care only.",[64,65],"Perinatal Depression","Fathers",[67,68,69,70],"cognitive behavioral therapy","paternal depression","perinatal depression","fathers","2026-08-11",{"date":73,"type":41},"2026-08-13",{"date":75,"type":22},"2026-09-15",{"date":77,"type":22},"2029-12-31",{"name":47,"class":48},1,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":19,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":23,"phases":93,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":79},"100651343","the-influence-of-plan-b-on-cardiovascular-health-100651343","NCT07759635","The Influence of Plan B® on Cardiovascular Health.","The Influence of a Single Dose of Emergency Contraception on Markers of Venous Thrombosis and Vascular Function in Young, Healthy Females.","LEVOH","Inclusion Criteria:\n\n1. Provide written informed consent.\n2. Pre-menopausal female.\n3. 18 - 35 years of age.\n4. Naturally cycling (i.e., not using any form of hormonal contraception for ≥ 3 months).\n5. Eumenorrheic (i.e., experiencing a predictable menstrual cycle lasting 21-45 days).\n6. In the surrounding Hamilton area, or able to visit McMaster for study visits.\n7. Not pregnant.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to the active substance levonorgestrel or to any ingredient in this formulation (i.e., levonorgestrel colloidal silicon dioxide, potato starch, magnesium stearate, talc, cornstarch, lactose monohydrate, or any ingredient\u002Fexcipient in the placebo capsule.\n2. Known or suspected pregnancy.\n3. At risk of the development of unwanted pregnancy within the past 72 hours.\n4. Known, suspected, or history of cardiovascular, metabolic, or musculoskeletal disease.\n5. Undiagnosed abnormal vaginal bleeding.\n6. Use of anti-HIV drugs, anticonvulsant drugs, antibiotics, rifampicin\u002Frifabutin, ulipristal acetate, Griseofulvin, Hypericum perforatum (St John's wort) or any other drug that may interfere with the normal pharmacokinetic or pharmacodynamic characteristics of the study intervention.\n7. Active or history of migraine.\n8. A condition or factor that would prevent the use of Plan B®.",true,"FEMALE","35 Years",{"count":92,"type":22},40,[61],"The goal of this double-blind randomized controlled trial is to learn about the impacts of a single dose of Plan B® on the cardiovascular system in young, health, premenopausal females. The main questions it aims to answer are:\n\n1. What is the short-term affect of Plan B® affect on the venous system?\n2. What is the short-term affect of Plan B® affect on the health of arteries?\n\nResearchers will compare a single dose of Plan B® (1.5 mg of levonorgestrel) to a placebo to see if Plan B® has unique effects on the cardiovascular system.\n\nParticipants will:\n\n1. Undergo baseline measurements of venous thrombosis markers, blood pressure, and measures of arterial function using ultrasound.\n2. Be randomized to either take a Plan B® or placebo pill\n3. Repeat baseline measurements of venous thrombosis markers, blood pressure, and measures of arterial function using ultrasound each hour, for 6-hours, and then 24- and 48- hours after taking the Plan B® or placebo pill.",[96,97],"Female","Premenopausal",[99,100,101,102],"Emergency contraceptives","Hormonal contraceptives","Venous thrombosis","Endothelial function","RECRUITING","2026-08-06",{"date":106,"type":41},"2026-08-12",{"date":108,"type":22},"2026-07-22",{"date":110,"type":22},"2027-09-01",{"name":47,"class":48},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":130,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100641615","antireflux-surgery-without-preoperative-esophageal-manometry-100641615","NCT07659080","Antireflux Surgery Without Preoperative Esophageal Manometry","Laparoscopic Toupet Fundoplication With or Without Preoperative Esophageal Manometry in Patients With GERD and Hiatal Hernia","NOMA","Inclusion Criteria\n\n1. Age ≥ 18 years\n2. Documented GERD and\u002For hiatal hernia (Type I, II, or small Type III) confirmed on EGD and\u002For imaging (i.e. CT scan or upper GI study) within 12 months\n3. Presence of at least one guideline-based indication for antireflux surgery:\n\n   1. Typical GERD symptoms (heartburn and\u002For regurgitation) refractory to or recurrent after adequate PPI therapy\n   2. PPI-dependent GERD with patient preference for surgical management\n   3. Extra-esophageal GERD symptoms (chronic cough, laryngitis, asthma) with pathologic reflux confirmed on ambulatory pH study\n   4. Symptomatic Type II\u002FIII paraesophageal hernia (postprandial pain, early satiety, dysphagia to solids)\n   5. Objective documentation of pathologic esophageal acid exposure on ambulatory reflux monitoring (24-hour pH-impedance or 48-hour Bravo pH capsule) confirming GERD diagnosis, performed within 12 months of enrollment\n4. Mellow-Pinkas dysphagia score = 0 at baseline (no overt dysphagia)\n5. Eckardt score \\\u003C 1 (achalasia screening)\n6. Ability to provide informed consent and comply with 12-month follow-up.\n\nExclusion Criteria:\n\n1. Overt dysphagia (Mellow-Pinkas ≥ 1 or Eckardt ≥ 1)\n2. Prior esophageal or gastric surgery\n3. Known or clinically suspected achalasia or primary motility disorder\n4. Endoscopic stricture, mass, or luminal obstruction\n5. Giant paraesophageal hernia (Type IV, or Type III with \\>50% of stomach herniated intrathoracically)\n6. Connective tissue disease with esophageal involvement (e.g., scleroderma\u002FCREST)\n7. Active esophageal or gastric malignancy\n8. Pregnancy\n9. BMI \\> 40 kg\u002Fm² (patients with severe obesity who would be candidates for bariatric surgery should be referred for metabolic\u002Fbariatric evaluation, as per the multi-society GERD guideline recommending weight-loss surgery consideration in this population)\n10. Participation in another interventional trial within 30 days\n11. Prior esophageal manometry within 12 months demonstrating a major motility disorder (achalasia, absent contractility, distal esophageal spasm, hypercontractile esophagus); such patients should be managed per standard motility disorder pathways and are not candidates for this trial.",{"count":121,"type":22},96,[61],"The goal of this clinical trial is to learn if people can safely skip a test called esophageal manometry before surgery for acid reflux (gastroesophageal reflux disease, or GERD) or a hiatal hernia. Manometry measures the muscles of the food pipe using a thin tube passed through the nose. The test can be uncomfortable and can delay surgery. The main questions this study aims to answer are whether people can skip manometry and still have good swallowing one year after surgery, and whether skipping the test lowers discomfort, shortens the wait for surgery, and lowers cost. To answer this, researchers will compare two groups. One group will have surgery without manometry. The other group will have manometry first, the way it is usually done. Everyone will get the same operation, a partial wrap called a Toupet fundoplication, so the study tests the value of the test and not the surgery. Participants will be placed by chance into one of the two groups, have the same standard operation, and fill out short questionnaires about their swallowing before surgery and again at 3, 6, and 12 months after surgery. Researchers want to find out if skipping manometry works just as well as the usual approach for people who do not have trouble swallowing before surgery.",[125,126,127,128,129],"GERD","Hiatal Hernia","Heartburn","Paraesophageal Hernia","Gastroesophageal Reflux",[125,131,132,133,128],"hiatal hernia","fundoplication","Gastroesophageal Reflux Disease",{"date":135,"type":41},"2026-08-10",{"date":137,"type":22},"2026-10-01",{"date":139,"type":22},"2028-04-30",{"name":47,"class":48},2,{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":141},"100605945","protease-regulation-and-impact-of-sodium-as-mechanisms-of-inflammation-in-ibd-100605945","NCT07169123","Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD","PRISM-IBD","Inclusion Criteria:\n\n* 18 and 70 years of age\n* Crohn's disease diagnosis\n* Willing and able to sign written informed consent prior to study entry\n* Able to comply with the study procedures, in the opinion of the investigator\n\nExclusion Criteria:\n\n* Antibiotics, antibacterial agents, or probiotics, currently, or within the last 8 weeks\n* Alcohol or drug abuse\n* Pregnancy\n* Concurrent systemic disease and\u002For laboratory abnormalities considered by investigators to be a risk or that could interfere with data collection","70 Years",{"count":151,"type":22},300,"OBSERVATIONAL","The study looks at how eating salt affects gut health in people with Crohn's disease. The aim of the study is to find out whether eating more salt increases the breakdown of proteins in the gut and if this makes inflammation and symptoms worse. By studying the link between salt, gut bacteria and inflammation, the study hopes to improve diet advice for people with Crohn's disease. This research may help find specific foods that affect the disease and lead to better, more personalized nutrition plans.",[155],"Crohns Disease",[157,158,159,160],"sodium","Crohn's disease","proteases","diet","2026-07-29",{"date":163,"type":41},"2026-07-30",{"date":165,"type":41},"2025-08-18",{"date":167,"type":22},"2029-09-01",{"name":47,"class":48},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":88,"sex":18,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":79},"100649724","phase-4-safe-self-administration-of-flumist-to-improve-uptake-a-household-based-cluster-randomized-trial-100649724","NCT07739719","SAFE (Self-Administration of Flumist to ImprovE Uptake: A Household-Based Cluster Randomized Trial)","SAFE","Inclusion Criteria:\n\nHousehold: Households with at least one child aged 2 to 17 years, living in Burlington, Ontario Individual: 1) Residence in an eligible household 2) Age 2 years to 59 years\n\nExclusion Criteria:\n\nHousehold: Households where all members have received influenza vaccine in 2 years prior to the study.\n\nIndividual:\n\n1. Pregnancy\n2. Breast feeding\n3. Past serious allergic reaction to study vaccine components (including gentamicin, gelatin, or arginine) or to previous influenza vaccination\n4. Severe asthma or active wheezing\n5. History of Guillain-Barre syndrome within 6 weeks of receiving a previous influenza vaccine\n6. Children 2 to 17 receiving aspirin or salicylate -containing medications. Children who are not receiving aspirin should not receive aspirin for at least 4 weeks after receiving Flumist unless medically indicated.\n7. Severely immunocompromised person\n8. People who will provide care to severely immunocompromised persons for at least 2 weeks following vaccination or who share a household with an immunocompromised person.","2 Years","59 Years",{"count":179,"type":22},966,[25],"The flu is a health risk for Canadians. It causes up to 15,000 hospitalizations every year and is one of the top 10 causes of death. Getting a flu vaccine is the best way to prevent the flu and any severe complications. Unfortunately, many Canadians do not get the flu vaccine. A recent survey found that less than a quarter of healthy adults got the flu vaccine.\n\nIn Canada, current standard access to influenza vaccination is at physician offices, public health clinics, or pharmacy. Therefore, this study is testing a novel access route to influenza vaccine. This study will answer the question: \"Will self-administration at home of FLUMIST through a pharmacy pick up model increase uptake of influenza vaccination compared to usual care?\" FLUMIST is a needle-free vaccine given as a nasal spray.\n\nHouseholds will be randomly chosen to either be offered the FLUMIST vaccine that can be given at home or to make their own choice for the flu season, which may or may not include vaccination.",[183],"Influenza (Healthy Volunteers)","2026-07-28",{"date":186,"type":41},"2026-07-31",{"date":188,"type":22},"2026-10-15",{"date":190,"type":22},"2027-02-15",{"name":47,"class":48},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":79},"100557598","the-development-safety-and-feasibility-of-an-artificial-intelligence-powered-platform-nodeai-for-real-time-prediction-of-mediastinal-lymph-node-malignancy-during-endobronchial-ultrasound-staging-for-lung-cancer-100557598","NCT06540196","The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer","NodeAI","Inclusion Criteria:\n\n* Patients ≥ 18 years of age diagnosed with suspected or confirmed NSCLC based on CT and PET scans that are referred for chest staging by EBUS-TBNA\n* CT and PET scans completed\n\nExclusion Criteria:\n\n* Patients with cN0 disease AND peripheral tumors AND tumors \\\u003C 2 cm in diameter (those do not require chest staging)",{"count":200,"type":22},600,[61],"Lung cancer is the leading cause of annual cancer deaths globally, more than breast, prostate, and colon cancers combined. The staging of chest lymph nodes (LNs) is a crucial step in the lung cancer diagnostic pathway because it aids in treatment decisions - whether a patient is a candidate for lung resection, chemotherapy, radiation, or multimodal treatments. Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) is the current standard for chest nodal staging for non-small cell lung cancer (NSCLC), and guidelines mandate that Systematic Sampling (SS) of at least 3 chest LN stations be routinely performed for accurate staging. Unfortunately, EBUS-TBNA yields inaccurate results in 40% of patients, leading to misinformed treatment decisions. This proportion is much higher in patients with Triple Normal LNs \\[LNs that appear normal on computed tomography (CT) scans, positron emission tomography (PET) scans, and EBUS\\], which have been found to have a \\> 93% chance of being truly benign. This is because EBUS-TBNA is based on ultrasound, whose success highly depends on the skill of the person performing it (operator). When the operator makes an error, the entire procedure is jeopardized. This causes downstream delays in treatment due to repeated testing and ill-informed treatment decisions.\n\nOver the past decade, the investigator has been conducting a series of research studies and trials: the development and validation of the Canada Lymph Node Score (CLNS) - a surgeon-derived semi-quantitative measure of LN malignancy; an Artificial Intelligence (AI)-based version of the CLNS to predict malignancy; and a fully autonomous AI that learned to predict malignancy directly from ultrasound images, to introduce AI to the decision-making pathway in NSCLC. This resulted in the creation of an AI-powered software to predict malignancy in mediastinal LNs of patients with lung cancer. The software is currently housed in cloud storage and its applications are latent - which means that LN images must be uploaded to the software, and results are received at a future time. In its current form, the software is not ready for clinical application due to this latency. In this project, the investigator aims to build a point-of-care device which will house the software (NodeAI) and deliver real-time results to the surgeon, and this device will be tested in a clinical trial.",[204,205],"Lung Cancer","Non Small Cell Lung Cancer",{"date":163,"type":41},{"date":208,"type":41},"2025-01-10",{"date":210,"type":22},"2026-12-31",{"name":47,"class":48},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":235},"100478547","anteroposterior-versus-anterolateral-electrode-position-for-electrical-cardioversion-of-atrial-fibrillation-100478547","NCT05511389","Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation","A Randomized Controlled Trial of Anterior-posterior Versus Anterior-lateral Shock Vectors for Electrical Cardioversion of Atrial Fibrillation","SHOCK-VECTOR","Inclusion Criteria:\n\nConsenting adult patients scheduled for non-emergent electrical cardioversion of Atrial Fibrillation or Flutter\n\nExclusion Criteria:\n\n1. Insufficiently anticoagulation for cardioversion as per Canadian Cardiovascular Society guidelines or have not undergone trans-esophageal echocardiography to rule out left atrial thrombus\n2. Anatomic contraindication to anterolateral or anteroposterior placement (e.g. skin conditions or wounds)",{"count":221,"type":22},1750,[61],"Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart failure, poor quality of life and even death. Almost half a million deaths worldwide are expected to be related to atrial fibrillation by 2050, and many billions of dollars are spent on atrial fibrillation related healthcare in North America every year.\n\nWe believe health outcomes for patients with atrial fibrillation, and healthcare costs associated with treating atrial fibrillation could be improved by optimizing existing treatments for atrial fibrillation and maximizing the likelihood of restoring normal heart rhythm. This allows them to benefit from lower stroke risk, better heart function, fewer symptoms and increased quality of life. Restoring normal sinus rhythm earlier prevents atrial fibrillation from causing permanent structural damage to the heart that in turn, makes atrial fibrillation intractable. Furthermore, patients in whom initial attempts to control atrial fibrillation are unsuccessful frequently require more medications or invasive catheter ablation procedures which are costly and carry substantial risk.\n\nElectrical cardioversion is the main way physicians restore normal heart rhythm. In this procedure, the heart is \"shocked\" back into normal rhythm using two electrodes on the chest. Done correctly, this procedure is safe and effective. Many things are known about electrical cardioversion, for example, the best type and amount of electricity to use. What we don't know is the best position of the electrodes on the chest and whether applying direct, physical pressure to the electrodes makes cardioversion more successful. Our prior research suggests that improving positioning and applying pressure may improve cardioversion, but this finding needs to be verified with a rigorous, dedicated trial.\n\nThis study will demonstrate whether front-to-back, or front-to-side placement of the electrodes is more effective for electrical cardioversion of atrial fibrillation. We will also demonstrate whether manually applying pressure to the electrodes makes cardioversion more effective. Should our trial demonstrate a benefit for these techniques, we expect them to be universally applied around the world. Because hundreds of thousands of cardioversions are done each year, even small increases in cardioversion success means thousands fewer patients progress to needing more medications or invasive procedures to manage their atrial fibrillation.\n\nWe will study consenting adults presenting for non-urgent cardioversion of their atrial fibrillation. After explaining the study to participants and gaining their consent, we will randomly assign them to front-to-side or front-to-back electrode placement. Patients who remain in atrial fibrillation after the first shock will randomly receive either manual pressure or not. We will compare the success of cardioversion for front-side versus front-back electrode placement, and for manual pressure versus none. We will evaluate success by using electrocardiograms to assess for restoration of the heart rhythm back to normal.\n\nWe hypothesize that anterolateral electrode positioning is superior to anteroposterior electrode positioning. We also hypothesize that manual pressure is effective relative to none, when applied in patients who have had one unsuccessful shock already.",[225,226],"Atrial Fibrillation","Atrial Flutter","2026-07-15",{"date":229,"type":41},"2026-07-16",{"date":231,"type":41},"2023-02-22",{"date":233,"type":22},"2028-08",{"name":47,"class":48},4,{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":88,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":79},"100645747","the-creative-team-member-a-study-of-the-influence-of-ai-integration-timing-on-brainstorming-and-ideation-100645747","NCT07693803","The Creative Team Member: A Study of the Influence of AI Integration Timing on Brainstorming and Ideation","The Effect of Artificial Intelligence Integration Timing on Group Brainstorming and Ideation in Undergraduate Students: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Enrolled as a student in the designated summer research program\n* Able to provide voluntary informed consent\n* Proficient in reading and communicating in English (required to engage with the scenarios and the artificial intelligence tool)\n\nExclusion Criteria:\n\n-Not enrolled as an undergraduate student",{"count":244,"type":22},16,[61],"This study aims to examine how the timing of artificial intelligence (AI) integration during group brainstorming activities affects the creativity and ideation of participants. Undergraduate student participants will be randomly allocated into teams of four to complete a structured 12-minute brainstorming task. The study utilizes a three-group experimental design to compare three conditions: no AI access, AI access from the outset of the session, and AI access introduced halfway through the session. The standardized generative AI tool used is ChatGPT Pro. The creative output produced by each group will be evaluated by a panel of independent expert judges using the Consensual Assessment Technique (CAT).",[248],"Creativity",[250,251,252,253,254,255,256,257,258,248],"Artificial Intelligence","Generative AI","ChatGPT","Human-AI Collaboration","Problem Solving","Teamwork","Undergraduate Students","Ideation","Brainstorming","2026-07-11",{"date":261,"type":41},"2026-07-14",{"date":263,"type":22},"2026-07-20",{"date":75,"type":22},{"name":47,"class":48},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100645764","fatigue-in-long-covid-100645764","NCT07697261","Fatigue in Long COVID","Fatigue in Long COVID Managed With Conservative Care: An International, Randomized Controlled Trial (FALCON Trial)","FALCON","Inclusion Criteria:\n\n* The inclusion criteria for participants are:\n\n  1. Adults aged 18 to 65 years\n  2. Meeting the WHO clinical case definition for long COVID and\n  3. Self-reported experiencing long COVID symptoms such as fatigue, muscle pain, and brain fog.\n  4. Reporting a minimum score of ≥35 on the Checklist Individual Strength CIS-fatigue domain.\n  5. Able to speak and read English\n  6. Scoring higher in contemplation, action or maintenance scores than the precontemplation phase on the readiness to change questionnaire\n  7. Provides consent for study participation.\n  8. Consistent access to an internet-connected device (e.g., smartphone, tablet, laptop) that can facilitate access to the study interventions.\n\nExclusion Criteria:\n\n* The exclusion criteria are:\n\n  1. Long COVID participants whose presentation is primarily restricted to anosmia.\n  2. Participants with Post-Intensive Care Syndrome (PICS) or serious organic sequelae of COVID-19, such as structural lung injury attributable to mechanical ventilation or other organ damage requiring ongoing specialist management.\n  3. Participants who will not be able to attend intervention sessions or follow up visits due to anticipated significant life changes or relocation.\n  4. Unable to provide informed consent (e.g. cognitive disability, language barrier)\n  5. Co-morbidities that likely to impair function for as long or longer than long COVID\n  6. Current participation in psychotherapy, structured physical rehabilitation (e.g., physiotherapy or occupational therapy), or another trial that does not permit co-enrollment.","65 Years",{"count":276,"type":22},100,[61],"Long COVID affects about 6 in 100 people after a COVID-19 infection. It can cause ongoing problems like ongoing tiredness, muscle pain, and \"brain fog.\" We know very little about which treatments might be helpful for long COVID.\n\nThe goal of this trial is to compare two treatments for people with long COVID to try to manage their symptoms. The main question is to assess whether the Lightning Process is effective for people living with long COVID compared to activity pacing. Each person will be placed into one of the two groups randomly (by chance, like flipping a coin). Activity pacing helps people balance rest and daily activities. The Lightning Process teaches ways to change thought patterns and body responses to symptoms. We will include 100 adults with long COVID. Everything will be done online, including filling out surveys about health and daily life. The goal is to find out which approach helps people feel better and improve their daily activities.",[280],"Long COVID",[282,283,284,285,286],"long COVID","Lightning Process","activity pacing","post-exertional malaise","fatigue","2026-07-07",{"date":289,"type":41},"2026-07-13",{"date":291,"type":22},"2026-11",{"date":293,"type":22},"2028-12",{"name":47,"class":48},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":88,"sex":18,"minAge":303,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":79},"100579846","the-feasibility-of-implementing-syphilis-point-of-care-testing-into-a-prenatal-clinic-for-people-facing-barriers-to-care-100579846","NCT06829602","The Feasibility of Implementing Syphilis Point-of-care Testing Into a Prenatal Clinic for People Facing Barriers to Care","PREnatal Syphilis Point-of-care ScreenING in an Urban Low-barrier Clinic: A Prospective Single Arm Feasibility Trial","PRESSING","1. Pregnant people\n\n   Inclusion Criteria:\n   * Pregnant clients with at least one risk factor for syphilis infection:\n\n     1. Substance use or accessed addiction services in the past 1 year\n     2. Unstable housing in the past 1 year\n     3. Multiple sexual partners in the past 1 year\n     4. History of a sexually transmitted or blood-borne infection (STBBI)\n     5. Late to prenatal care (initial prenatal visit \\>20 weeks)\n   * Eligible for syphilis screening at that clinic visit, as per Public Health guidelines\n\n   Exclusion Criteria:\n   * Previous syphilis diagnosis\n   * Not competent to consent to study participation\n2. Sexual partners\n\nInclusion Criteria:\n\n* Sexual partners of pregnant clients who are newly diagnosed with syphilis\n* Physically present in the clinic\n\nExclusion Criteria:\n\n* Previous syphilis diagnosis\n* Not competent to consent to study participation","13 Years","49 Years",{"count":306,"type":22},77,[61],"The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV.\n\nThe main questions the study aims to answer are:\n\n* How often do pregnant people at risk of syphilis agree to the rapid test?\n* How well do healthcare providers perform the rapid test?\n* Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners?\n\nParticipants will:\n\n* Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and\n* Share information about their health, pregnancy, and syphilis treatment (if applicable).",[310],"Syphilis",[312,313,314,315,316],"syphilis","pregnancy","access to care","acceptability","point-of-care test","2026-07-03",{"date":287,"type":41},{"date":320,"type":41},"2025-06-25",{"date":322,"type":22},"2026-12",{"name":47,"class":48},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":331,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":339,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":79},"100644705","brain-wave-informed-non-invasive-brain-stimulation-improving-neural-networks-of-working-memory-in-dementia-a-proof-of-concept-study-100644705","NCT07673770","Brain Wave Informed Non-invasive Brain Stimulation: Improving Neural Networks of Working Memory in Dementia: a Proof-of-concept Study","BWIBS-WM","Inclusion Criteria:\n\n* Individuals must be diagnosed with Alzheimer's Disease or related dementias by a clinician.\n* Individuals must exhibit adequate oral communication skills and cognitive function sufficient to obtain a score above 10 on the MMSE\n* Instructions will be delivered in English; therefore participants must demonstrate an understanding of instruction provided in English.\n* Individuals must be at least 55 years or older\n\nExclusion Criteria:\n\n* Contraindications to TMS; presence of a pacemaker, metal\u002Felectrical\u002Fmagnetic implants not including titanium, known history of untreated or uncontrolled psychological disorders, pregnancy, history of seizure or diagnoses of epilepsy, are taking any prescription medications that increase the risk of seizure.\n* Allergy to rubbing alcohol, which is needed to prepare electromyography for TMS","55 Years",{"count":333,"type":22},30,[61],"Working memory helps us hold information for a short time so one can think and make decisions. It keeps thoughts on track. As one gets older, working memory gets weaker. In people with dementia, it gets much worse, making it harder to talk with others, follow directions, or remember things like shopping lists.\n\nThis may happen because brain waves that support working memory fall out of sync. Researchers can see these brain waves using a test called EEG. In this study, the investigators will try to get these brain waves back in sync using a safe, non-invasive form of brain stimulation called transcranial magnetic stimulation (TMS), and will time it to each person's brain waves to make it more effective. The goal is to improve working memory in people with dementia. If successful, dementia patients may be able to be more independent taking pressure off their families.",[337,338],"Dementia","Alzheimer s Disease",[337,340,341,342,343],"Alzheimer's Disease","transcranial magnetic stimulation","eeg","electroencephalography","2026-07-02",{"date":287,"type":41},{"date":287,"type":22},{"date":348,"type":22},"2028-08-01",{"name":47,"class":48},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":359,"briefSummary":361,"conditions":362,"keywords":365,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":79},"100644478","phase-3-tirzepatide-in-the-treatment-of-cannabis-use-disorder-100644478","NCT07671248","Tirzepatide in the Treatment of Cannabis Use Disorder","A 12-Week Phase 3 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Tirzepatide-Assisted-Psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study","Inclusion Criteria:\n\n* Adults aged 18 and above\n* DSM-5 Cannabis Use Disorder diagnosis of at least moderate severity (4+ DSM-5 symptoms)\n* 4 or more days of cannabis use per week\n* Treatment seeking\n* A Body Mass Index (BMI) ≥ 22\n\nExclusion Criteria:\n\n* Meet DSM-5 criteria for Cluster A or B personality disorders and\u002For unstable current bipolar disorder, schizophrenia, or psychotic disorder\n* Comorbid severe DSM-5 Major Depressive Disorder\n* Present a serious suicide risk or who are likely to require psychiatric hospitalization during the course of the study, as determined by the study physician and Columbia Suicide Severity Rating Scale\n* Any other mental health condition deemed incompatible by the study team\n* Meet DSM-5 criteria for alcohol or substance use disorder for any substance other than cannabis or tobacco in the past 6 months\n* Positive urine drug screen for any substance except cannabis\n* Concurrent addiction-focused psychotherapy in the past 6 months\n* Unstable management of an existing mental health condition or anticipation of a change to the treatment over the next 3 months\n* A personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2\n* Current unstable medical condition\n* A lifetime diagnosis of Diabetes\n* Females who are pregnant\u002Fnursing, or individuals in reproductive age who do not consent to using birth control during the study\n* Concomitant treatment with: other GLP-1 agonists, Contrave, bupropion, naltrexone, acamprosate within the past year. No lifetime treatment with tirzepatide.\n* Significant literacy, visual, or hearing problems\n* Co-enrollment in a clinical drug trial",{"count":358,"type":22},15,[360],"PHASE3","Cannabis is the most commonly used psychoactive substance in Canada. A sub-group of cannabis users develop Cannabis Use Disorder (CUD). CUD is a pattern of cannabis use that results in impairment in functioning, symptoms of tolerance, withdrawal, and distress. Several pharmacological and psychosocial interventions have been evaluated for their efficacy in treating CUD, however they lack high success rates. GLP-1RA's have shown promising results in reducing food and alcohol cravings and intake. Tirzepatide acts as both a GLP-1RA and a glucose-dependent insulinotropic polypeptide receptor agonist. Tirzepatide has been reported to reduce alcohol consumption, and therefore may have promising effects as a treatment for CUD. This study aims to evaluate the feasibility and tolerability of weekly injections of Tirzepatide combined with Motivational Enhancement Therapy in adults with CUD. This trial will be the first to examine the potential therapeutic effects of Tirzepatide in CUD.",[363,364],"Cannabis Use Disorder, Moderate","Cannabis Use Disorder, Severe",[366,367,368],"Cannabis Use Disorder","Motivational Enhancement Therapy","Tirzepatide","2026-06-29",{"date":371,"type":41},"2026-07-01",{"date":373,"type":22},"2026-08-01",{"date":375,"type":22},"2028-07-31",{"name":47,"class":48},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":274,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":408,"leadSponsor":409,"locationsCount":141},"100642424","feasibility-of-a-community-integrated-isometric-handgrip-exercise-program-and-its-preliminary-effects-on-blood-pressure-and-cognitive-function-in-older-adults-100642424","NCT07648498","Feasibility of a Community-Integrated Isometric Handgrip Exercise Program and Its Preliminary Effects on Blood Pressure and Cognitive Function in Older Adults","Inclusion Criteria:\n\n* 65 years of age or older\n* Currently attending the Physical Activity Centre of Excellence at McMaster University\n* English speaking\n* Diagnosed with hypertension or elevated blood pressure\n\nExclusion Criteria:\n\n* Current or prior participation in chronic isometric exercise\n* Unstable angina.\n* Uncontrolled hypertension\n* Uncontrolled heart failure and\u002For arrhythmias\n* Recent myocardial infarction or electrocardiography changes\n* Complete heart block\n* Carpal tunnel syndrome\n* Arthritis that may be aggravated by handgrip exercise\n* Changes to the type and\u002For dose of blood pressure medications within 3 months of starting the study.",{"count":333,"type":22},[61],"The goal of this clinical trial is to evaluate whether a short, supervised isometric handgrip exercise program is feasible and acceptable for older adults with elevated blood pressure or hypertension. It will also explore whether this type of exercise may improve blood pressure and cognitive function.\n\nThe main questions it aims to answer are:\n\n* Is this handgrip exercise program practical and acceptable for older adults to participate in within a community exercise setting?\n* Does participation in the program lead to changes in blood pressure and cognitive function?\n\nResearchers will compare two handgrip devices to determine whether the method of delivering the exercise influences feasibility and outcomes.\n\nParticipants will:\n\n* Be randomly assigned to use one of two handgrip devices.\n* Complete supervised exercise sessions twice per week for 4 weeks.\n* Perform brief handgrip contractions at a set intensity during each session.\n* Complete blood pressure and cognitive assessments before and after the program.",[387,388],"Hypertension","Elevated Blood Pressure",[390,391,387,392,393,394,395,396,397,398,399,400,401,402,403],"Older Adults","Isometric Handgrip Exercise","Feasibility","Cognition","Exercise Intervention","Blood Pressure","Community-based exercise","Pilot study","Aging","Acceptability","Handgrip training","Isometric Exercise","Cognitive function","Cardiovascular health","2026-06-11",{"date":406,"type":41},"2026-06-15",{"date":184,"type":22},{"date":75,"type":22},{"name":47,"class":48},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":417,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":79},"100642045","rhythm-psychophysics-with-parkinsons-patients-100642045","NCT07647913","Rhythm Psychophysics With Parkinson's Patients","RPPD","Inclusion Criteria:\n\n* Parkinson's Disease diagnostic\n* Stage 1 or 2 Hoenh-Yahr scale\n* Taking immediate-release Levodopa\n* MoCA score of 26 or above\n\nExclusion Criteria:\n\n* Dementia\n* Other neurodegenerative disease\n* History of substance abuse\n* History of hearing disorders\n* History of neuropsychiatric disease","40 Years","80 Years",{"count":420,"type":22},34,[61],"The goal of this interventional study is to understand how the rhythmic abilities of individuals in the early stages of Parkinson's Disease (PD) are impacted by their levels of dopamine. The main questions it aims to answer are:\n\n* Does dopamine shelter the ability to generate and maintain a regular tapping rhythm in the presence of disrupting sensory information?\n* Does dopamine allow the adaptation of tapping speed in the presence of changing sensory information?\n* Is the engagement of the motor system useful to improve the detection of changes in the tempo of sensory information?\n\nParticipants will be asked to perform a battery of simple rhythmic tasks On and Off medication to evaluate the effect of dopamine on their rhythmic skills.",[424],"Parkinson Disease(PD)",[426,427,428,429,430,431,432],"Parkinson Disease","PD","Rhythm","Sensorymotor synchronization","Perceptual timing","Motor timing","Interval timing","2026-06-09",{"date":406,"type":41},{"date":436,"type":22},"2026-09-01",{"date":438,"type":22},"2027-10-31",{"name":47,"class":48},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":448,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":470,"locationsCount":79},"100581512","guided-self-help-for-eating-disorders-implementation-study-100581512","NCT06851273","Guided Self Help for Eating Disorders Implementation Study","National Implementation of Highly Efficient Evidence-Informed Treatment for Youth With Eating Disorders","GSHimplement","Inclusion Criteria:\n\n* Family including an adolescent with a confirmed diagnosis of Anorexia nervosa according to DSM-5-TR criteria.\n* Access to computer and internet connection\n* Have the capacity to speak, write, and understand English or French\n* Therapist\u002Fcoaches are licensed mental health clinician with experience in eating disorder treatment\n\nExclusion Criteria:\n\n* Adolescent has a current physical or mental disorder that requires hospitalization and\u002For prohibits the use of psychotherapy\n* Adolescent has a current dependence on drugs or alcohol\n* Adolescent has a current physical condition known to influence weight or eating (pregnancy, diabetes mellitus)\n* Adolescent has expected body weight of less than 75%\n* Adolescent\u002Ffamily has undergone four or more sessions of FBT for anorexia nervosa at any time\n* Does not have the capacity to speak, write, and understand English or French\n* Does not have access to computer and internet connection\n* Professionals are not licensed mental health professionals with experience in eating disorder treatment.","12 Years","100 Years",{"count":451,"type":22},90,[61],"Eating disorders are amongst the most understudied illnesses affecting young women in Canada. Further, mortality rates are amongst the highest of all psychiatric illnesses. Despite their high prevalence and mortality rates, research into adolescent eating disorders is underfunded in Canada. In addition to the problem of research underfunding, healthcare system underfunding exists - creating long waiting lists and fragmented care for children and youth with eating disorders. More efficient treatments are urgently needed to reduce wait times and provide expedited care to adolescents on eating disorder waitlists. The current study aims to assess whether implementing a virtual parent-lead therapy, Guided Self Help Family-Based Therapy (GSH FBT) might alleviate wait times for eating disorder services and also reduce eating disorder symptomatology in young people with anorexia nervosa. This study also aims to determine the experiences of both families and medical teams of GSH FBT implementation as an intervention.",[455],"Eating Disorders",[457,458,459,460,461,462],"Anorexia nervosa","Mental disorders","Adolescent eating disorders","Psychotherapy intervention","Guided self help therapy","Family-based treatment","2026-05-01",{"date":465,"type":41},"2026-05-07",{"date":467,"type":41},"2026-04-28",{"date":469,"type":22},"2027-12-30",{"name":47,"class":48},{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":480,"briefSummary":481,"conditions":482,"keywords":485,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":499},"100638954","optimized-recruitment-to-drive-equitable-research-in-stroke-empowering-decision-making-ordered-100638954","NCT07576647","Optimized Recruitment to Drive Equitable Research in Stroke, Empowering Decision-making (ORDERed)","ORDERed","Participants eligible for StrokeGoRed hospitalized cohort are eligible for ORDERed:\n\nInclusion Criteria:\n\n* All patients, regardless of age or baseline disability, seen in urgent TIA\u002Fstroke clinics and referred from the emergency department for suspected TIA or minor stroke will be included over one calendar year\n\nExclusion Criteria:\n\n* There are no exclusion criteria\n\nParticipants eligible for StrokeGoRed hospitalized cohort are eligible for ORDERed:\n\nInclusion Criteria:\n\n* Ischemic stroke\n* Intracerebral hemorrhage\n\nExclusion Criteria:\n\n* Cerebral venous thrombosis\n* Subarachnoid hemorrhage\n* Subdural hemorrhage\n* Intracranial hemorrhage due to trauma or underlying mass\n* Clinical transient ischemic attack without evidence of infarct on neuroimaging\n* Imaging abnormality (e.g., dissection, carotid stenosis, vessel irregularity) without imaging or clinical evidence of stroke\n* Stroke that occurred while being admitted for another reason\n* Stroke that started more than 14 days prior to admission\n* Stroke initially treated outside of Canada\n* Stroke where inpatient stroke or neurology service was not consulted",{"count":479,"type":22},1600,[61],"Stroke is a major health issue, especially for women, who are more likely than men to have worse outcomes and lower quality of life after a stroke. Yet, women are under-represented in stroke research, which limits how well treatments work for them. This study aims to change that by testing a new way to recruit women into stroke research using the ORDER toolkit, a set of easy-to-understand, women-focused materials like brochures and videos co-designed with patients. This new approach will be compared to the usual way of recruiting patients. The study will track how many people join, how long it takes to make a decision, and what influences participation. Patients and research coordinators will also share their feedback on the process. Our goal is to make stroke studies more inclusive so that research findings benefit everyone equally.",[483,484],"Stroke","Stroke (CVA) or Transient Ischemic Attack",[486,487,488,489,490],"Stroke rehabilitation","Clinical Trial","Informed consent","Diversity, Equity, Inclusion","Sex","2026-04-30",{"date":493,"type":41},"2026-05-08",{"date":495,"type":22},"2026-04",{"date":497,"type":22},"2029-08",{"name":47,"class":48},3,{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":522,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":535,"locationsCount":79},"100630348","mindfulness-in-fracture-recovery-and-reduction-of-opioid-reliance-evaluating-the-feasibility-of-implementing-a-brief-mindfulness-based-intervention-to-manage-pain-and-anxiety-before-and-after-fracture-surgery-100630348","NCT07486505","Mindfulness in Fracture Recovery and Reduction of Opioid Reliance: Evaluating the Feasibility of Implementing a Brief, Mindfulness-based Intervention to Manage Pain and Anxiety Before and After Fracture Surgery","Mindfulness in Fracture Recovery and Reduction of Opioid Reliance (MIRROR): Evaluating the Feasibility of Implementing a Brief, Mindfulness-based Intervention to Manage Pain and Anxiety Before and After Fracture Surgery","MIRROR","The inclusion criteria are:\n\n1. Adults 18 years of age or older; and\n2. Presenting to the hospital with an open or closed appendicular fracture requiring internal fixation. Patients with multiple fractures may be included.\n\nThe exclusion criteria are:\n\n1. Does not have the English-language skills required to participate in trial interventions (in the judgement of site research personnel);\n2. Cognitive impairment (including traumatic brain injury);\n3. Auditory or visual impairment that would inhibit ability to receive intervention;\n4. Current incarceration;\n5. Concomitant injury which, in the opinion of the attending surgeon, is likely to impair function for as long as or longer than the patient's extremity fracture;\n6. Previously completed a standardized mindfulness program (e.g., MBSR) or regularly (e.g., daily) practice mindfulness;\n7. Active psychosis;\n8. Active suicidality;\n9. Stress fracture;\n10. Fragility fracture;\n11. Currently enrolled in a study that does not permit co-enrolment in other trials;\n12. Not willing to participate in the intervention;\n13. No provision of informed consent; or\n14. Other reason as approved by the Data Coordinating Centre.",{"count":509,"type":22},50,[61],"Breaking a bone is not only physically painful but also emotionally overwhelming. Patients often experience intense pain, anxiety, and uncertainty as they are rushed to hospital, undergo emergency treatment, and prepare for surgery. After surgery, many continue to struggle with pain and rely on opioid medications, which carry serious risks including addiction. In the context of our current opioid epidemic, it's critical that alternative treatment strategies are urgently evaluated.\n\nMindfulness is a practice that helps people focus on the present and has been shown to reduce stress and pain in other settings. In this trial, patients with broken arms or legs who need surgery at Hamilton General Hospital will be randomly assigned to one of two groups who will listen to a two-part, audio recording before and after surgery. Those in the interventional group will engage in a 7-minute audio-guided mindfulness exercise before surgery to help reduce anxiety, and another 7-minute audio-guided mindfulness exercise after surgery to help manage pain. Those in the control group will listen to a 7-minute educational audio recording before surgery and again after surgery.\n\nThe main goal is to see if this approach is practical-can enough patients be recruited, and will they complete the audio recordings? The study will also look at early signs of whether the intervention helps reduce pain, anxiety, and opioid use six weeks after surgery. If feasible, a larger study can be conducted to determine if these exercises can help patients manage pain and reduce their need for opioids after surgery.\n\nIf successful, this simple, low-cost approach could be widely used in hospitals to support recovery and reduce reliance on pain medications.",[513,514,515,516,517,518,519,520,521],"Orthopaedic Fractures","Orthopaedic Trauma Fractures and Non-unions","Orthopaedic Trauma","Orthopaedic Surgery","Orthopaedic Related Pain (Musculoskeletal Pain)","Anxiety Acute","Anxiety After Surgery","Opioid Use","Opioid Use After Surgery",[523,524,525,526,527,528],"fractures","mindfulness","pain management","fracture surgery","opioid use","anxiety","2026-04-06",{"date":531,"type":41},"2026-04-07",{"date":463,"type":22},{"date":534,"type":22},"2026-10-30",{"name":47,"class":48},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":18,"minAge":543,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":23,"phases":546,"briefSummary":547,"conditions":548,"keywords":551,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":141},"100632819","feasibility-of-the-transitioned-framework-for-youth-and-young-adults-with-eating-disorders-100632819","NCT07518641","Feasibility of the TransitionED Framework for Youth and Young Adults With Eating Disorders","TransitionED 3","Inclusion Criteria:\n\nYouth and Young Adults (YYA):\n\n* Currently receiving paediatric eating disorder care at a participating study site.\n* Age 16 years or or older (approaching age-based transition to adult-care)\n* Expressed interest in transitioning to adult eating disorder care or other appropriate adult mental health services\n* Identified by the clinical team as appropriate to begin formal transition planning (e.g., sufficient transition readiness and interest in ongoing care)\n* Able and willing to provide informed consent\u002Fassent (as applicable at the site) and participate in study procedures\n\nCaregivers:\n\n* One caregiver (e.g., parent\u002Flegal guardian) of a participating YYA\n* Able and willing to provide informed consent and participate in study procedures (including questionnaires and interviews)\n\nClinicians (intervention deliverers):\n\n* Patient facing clinician at a participating site who provides transition support for participating YYA\u002Fcaregivers and is responsible for delivering intervention components (e.g., joint meeting(s), communication\u002Fcoordination related to the transition).\n* Able and willing to provide informed consent and participate in study procedures (e.g., focus groups)\n\nImplementation Team Members:\n\n* Program leadership\u002Fmanagers\u002Fsenior clinicians at a participating site involved in implementation of the intervention at that site.\n* Able and willing to provide informed consent and participate in study procedures (e.g., focus group).\n\nExclusion Criteria:\n\nYYA:\n\n* Not receiving pediatric eating disorder care at a participating site.\n* Under age 16 years\n* Does not express interest in transitioning to adult eating disorder care or other appropriate adult mental health services.\n* Not identified by the clinical team as ready\u002Fappropriate to engage in formal transition planning during the study period (e.g., insufficient transition readiness or not currently at the transition-planning stage).\n* Unable to provide informed consent\u002Fassent or unable to participate in study procedures (e.g., due to significant cognitive\u002Fcommunication barriers as determined by the clinical\u002Fresearch team).\n\nCaregivers:\n\n* Not the caregiver of an enrolled YYA (only one caregiver per YYA is enrolled).\n* Unable to provide informed consent or participate in study procedures.\n\nClinicians and Implementation Team Members:\n\n* Not affiliated with a participating site or not in an eligible role as defined above.\n* Peripheral providers who may be involved in care but are not enrolled as participants (e.g., family physicians or adult providers who might attend a joint meeting).\n* Unable to provide informed consent or participate in study procedures.","16 Years",{"count":545,"type":22},60,[61],"Moving from pediatric (children's) health care to adult health care can be challenging for youth and young adults with eating disorders. Many young people and families report feeling unprepared, unsure of what to expect, and worried about losing support during this time. Gaps in care during this transition can increase stress and make recovery more difficult.\n\nThis study is testing a structured transition support program called the TransitionED framework. The goal is to see whether this program can be successfully used in real hospital settings and whether youth, caregivers, and clinicians find it helpful.\n\nThe TransitionED framework is designed to help youth and families prepare for the move to adult care. It includes:\n\n1. A transition planning package for youth\n2. A separate planning package for caregivers\n3. At least two guided transition meetings with a clinician\n4. A short \"Personal Transition Profile\" written by the youth to help new adult providers understand them better\n5. Optional virtual peer support sessions for youth and for caregivers\n6. Tools to help pediatric and adult providers communicate more clearly\n\nYouth who are 16 years or older and currently receiving care in a participating pediatric eating disorder program may be invited to join, along with one caregiver. Clinicians and program leaders will also take part to help deliver and evaluate the program.\n\nParticipants will complete surveys at the beginning of the study, about two months later, and six months after finishing the program. Some participants will also take part in interviews to share their experiences.\n\nThis study is focused on feasibility. That means the main goal is to learn whether this transition program is practical, acceptable, and workable in everyday clinical care. What we learn will help improve transition support for youth and young adults with eating disorders in the future.",[549,550],"Eating Disorders in Adolescence","Transition of Care",[552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568],"eating disorders","healthcare transitions","Transition to Adult Care","Adolescent health","Young adults","Paediatric to adult care","Continuity of care","Mental Health Services","Implementation science","Feasibility study","Mixed Methods","Clinical Practice guidelines","Transition readiness","TRAQ","Peer support","Eating disorder treatment","Knowledge translation","2026-04-02",{"date":571,"type":41},"2026-04-08",{"date":573,"type":22},"2026-05",{"date":575,"type":22},"2028-03-31",{"name":47,"class":48},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":18,"minAge":585,"maxAge":586,"enrollmentInfo":587,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":604,"locationsCount":79},"100630543","shape-trial-skin-health-and-allergy-prevention-exposure-100630543","NCT07489040","SHAPE Trial: Skin Health and Allergy Prevention Exposure","Multi-component Package for Skin Health and Allergen Exposure Strategy to Prevent Food Allergy","SHAPE","Inclusion Criteria:\n\n1. Healthy singleton, neonates born at term (gestational age ≥37 weeks) (e.g. newborn without complications such as severe respiratory conditions, major congenital abnormalities, severe inborn errors of immunity \\[e.g. severe combined immunodeficiency\\], severe neonatal infections, neurologic impairment, and major gastrointestinal disorders).\n2. The newborn has any or at least one of the following risk factors: is an only child (no live siblings); first-degree relatives (parents and\u002For siblings) with history of food allergy, allergic rhinitis\u002Fconjunctivitis, asthma, or atopic dermatitis.\n3. Parent(s)\u002Fguardian provided informed consent for the child's study participation.\n\nExclusion Criteria:\n\n1. Newborns born to mothers with positive routine prenatal screening for any of the vertically transmitted diseases (e.g. hepatitis B, hepatitis C, active syphilis or genital herpes simplex, Chlamydia trachomatis, gonorrhea and human immunodeficiency virus \\[HIV\\]) that may prevent adherence to any of the recommendations of the environmental packages.\n2. Inability to adhere to the study procedures, e.g. severe maternal conditions (e.g. eclampsia, life-threatening conditions requiring intensive care admission) or neonatal skin conditions that require specific care practices.\n3. Ongoing participation in another interventional study (e.g. trials involving skin care with topical creams, medication or interventions related to allergy prevention) that may interfere with the current study.\n4. No access to phone, internet, or email (requirements to contact participant\u002Fguardian).\n5. Planning to move out of the province within 12 months of study enrollment.","37 Weeks","42 Weeks",{"count":588,"type":22},64,[61],"The goal of this clinical trial is to determine if a multi-component environmental package (MEP) can prevent food allergies among infants at risk of developing food allergies in early life.\n\nResearchers will compare the multi-component environmental package to regular care to see if the MEP works to prevent food allergies. Participants will:\n\n* Be assigned to the multi-component environmental package or regular care once their baby is born\n* Complete a weekly diary\n* Attend in-office visits at 4 and 12 months of age\n* Complete web-based questionnaires at 4, 6, 9 and 12 months of age",[592],"Allergy and Immunology",[594,595,596,597],"Allergy","Allergy prevention","Skin health","Food allergy","2026-03-31",{"date":529,"type":41},{"date":601,"type":22},"2026-04-01",{"date":603,"type":22},"2028-12-31",{"name":47,"class":48},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":615,"briefSummary":616,"conditions":617,"keywords":621,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":79},"100606923","technology-enabled-collaborative-care-for-diabetes-and-mental-health-100606923","NCT07181863","Technology-Enabled Collaborative Care for Diabetes and Mental Health","Bridging Gaps, Enhancing Wellbeing: Examining the Effectiveness of the Technology-Enabled Collaborative Care for Diabetes and Mental Health (TECC-DM) Model","TECC-DM","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Diagnosed with type 2 diabetes (T2D)\n* Experiencing mental health challenges, defined as:\n* Hospital Anxiety and Depression Scale (HADS) score ≥8 on either subscale OR\n* Diabetes Distress Scale (DDS) score ≥2\n* Community-living\n* Able to communicate verbally in English\n* Residing in Ontario during study participation\n\nExclusion Criteria:\n\n* Diagnosis of severe mental illness (e.g., schizophrenia, psychotic disorder)",{"count":614,"type":22},160,[61],"Managing both type 2 diabetes and mental health challenges can be difficult, and many people do not receive care that supports both. This study looks at how virtual health coaching and support from interdisciplinary care teams can help people better manage their health.\n\nThe purpose of this study is to test the effectiveness of a virtual health coaching program for adults living with type 2 diabetes and mental health challenges compared to usual care. The Technology-Enabled Collaborative Care for type 2 Diabetes and Mental health (TECC-DM) program includes weekly coaching calls, support from an interdisciplinary care team, and online tools to aid self-management. The findings from this study will be used to help improve services for people who have type 2 diabetes and co-occurring mental health symptoms.",[618,619,620],"Type 2 Diabetes","Mental Health","Diabetes Distress",[622,623,624,625],"type 2 diabetes","diabetes distress","technology","collaborative care","2026-03-28",{"date":569,"type":41},{"date":629,"type":41},"2025-03-16",{"date":631,"type":22},"2027-12",{"name":47,"class":48},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":18,"minAge":448,"maxAge":19,"enrollmentInfo":641,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":643,"conditions":644,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":650,"leadSponsor":651,"locationsCount":79},"100628295","early-arthroscopic-stabilization-versus-rehabilitation-of-the-shoulder-in-adolescents-with-a-traumatic-first-time-anterior-shoulder-dislocation-episode-100628295","NCT07459777","Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anterior Shoulder Dislocation ePisode.","Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anterior Shoulder Dislocation ePisode: A Pilot Prospective CohorT Study (PROMPT-Cohort)","PROMPTCohort","Inclusion Criteria:\n\n1. Males and females between the ages of 12 and 18, inclusive\n2. Patients with a first-time traumatic anterior glenohumeral dislocation within the past 5 months\n3. Anterior glenohumeral dislocation confirmed by radiography, reduction required by medical personnel, or demonstration of anterior apprehension on physical examination following injury to the shoulder\n4. MRI or MRA demonstrating disruption of the glenohumeral soft tissues (including the labrum, periosteum, or inferior glenohumeral ligament)34 relating to instability\n5. Patients who have the ability to speak, understand, and read the language of the clinical site\n6. Provision of informed consent (age 18) or parental consent (ages 12-17, inclusive)\n7. Provision of informed child assent (ages 12-17, inclusive)\n\nExclusion Criteria:\n\n1. Previous dislocation episodes or instability of the affected shoulder\n2. Previous surgeries involving the affected shoulder\n3. History or clinical exam findings of generalized ligamentous laxity (defined as a Beighton score of 4 or more points)35\n4. History of multi-directional instability of either shoulder\n5. Concomitant fracture of the tuberosity, humerus, or glenoid (excluding a Bankart or Hill Sachs lesion)\n6. Bony Bankart lesion exceeding 15% of the glenoid surface (using the best-fit circle method on MRI)36\n7. Hill Sachs lesion exceeding 15% of the humeral diameter (Measured on transaxial slice of MRI similar to Salomonsson et al.)37\n8. A neurological injury of the affected arm\n9. Patients who will likely have problems, in the judgement of the investigator, with maintaining follow-up\n10. Any other reason(s) the investigator feels is relevant for excluding the patient",{"count":333,"type":22},[61],"Each year within Canada and the US, more than 30,000 children and adolescents will have an injury to their shoulder resulting in a shoulder dislocation. Although the current practice is to manage this initial dislocation without surgery, the vast majority of these children and adolescents will, unfortunately continue to have instability episodes of their shoulder. Recurrent instability can cause damage to the bones and cartilage that form the shoulder resulting in potentially more difficult surgical stabilization, and possibly long-term sequela. To that effect, there is increasing interest to consider early surgical stabilization in this population. This pilot randomized controlled trial (RCT) will evaluate the feasibility of conducting a larger RCT assessing the effect of early arthroscopic stabilization compared to rehabilitation on the rate of repeat shoulder dislocations (recurrent instability), pain, and shoulder function among adolescents (aged 12-18 years) with first-time shoulder dislocations. These patients will be followed for one year.",[645],"Shoulder Dislocation","2026-03-09",{"date":648,"type":41},"2026-03-11",{"date":601,"type":22},{"date":348,"type":22},{"name":47,"class":48},{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":18,"minAge":659,"maxAge":4,"enrollmentInfo":660,"targetDuration":4,"studyType":23,"phases":661,"briefSummary":662,"conditions":663,"keywords":667,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":674,"lastUpdatePostDateStruct":675,"startDateStruct":677,"completionDateStruct":678,"leadSponsor":680,"locationsCount":681},"100628052","using-music-during-wound-care-among-seniors-with-pressure-injuries-100628052","NCT07456618","Using Music During Wound Care Among Seniors With Pressure Injuries","Investigating the Use of Music During Wound Care","Inclusion Criteria:\n\n* 60 years or older\n* Has a stage II, III, or IV pressure injury\n\nExclusion Criteria:\n\n* Designated as end of life and\u002For has a Kennedy terminal pressure injury\n* Has an unstageable pressure injury\n* The pressure injury has necrotic tissue or necrotic bone present\n* The pressure injury is infected\n* The pressure injury is caused by a medical device in that area\n* Severe to profound hearing loss that is not corrected by a hearing aid or other assistive hearing device.","60 Years",{"count":509,"type":22},[61],"Pressure injuries (also known as pressure wounds or bed sores) are increasingly common among older adults living in care homes. These wounds often require regular dressing changes, which can be uncomfortable for some.\n\nThe researchers believe that listening to music during wound care may have an effect on pain, wound healing, and the overall wound care experience, compared with wound care without music.\n\nThe goal of this clinical study is to test this idea by examining whether listening to music before and during wound care is linked to differences in pain, wound healing, and the overall wound care experience in older adults with pressure injuries.\n\nThe main questions this study aims to answer are:\n\nDoes listening to music before and during pressure injury care affect pain during wound care? Does listening to music before and during pressure injury care affect how pressure injuries heal over time? Does listening to music affect the overall experience of pressure injury care? Researchers will compare wound care with music to wound care without music to better understand whether music makes a difference.\n\nThe study will take place in eleven long-term care homes in Ontario. Participants will be residents aged 60 years and older who have a stage II, III, or IV pressure injury and who are already receiving regular wound care as part of their usual care. This study will not include residents who have infected or necrotic wounds, or who are at the end of life.\n\nParticipants will continue to receive the same wound care they would normally receive. Some homes will include music during wound care, and some homes will not.\n\nParticipants in homes using music will:\n\nListen to a playlist of music they personally enjoy for about 15 minutes before wound care begins Continue listening to the music during the wound care procedure Be able to change the volume or stop the music at any time Participants in homes not using music will receive the same standard pressure injury care without music.\n\nInformation for the study will come from clinical records that nurses already complete during routine wound care, such as notes about pain and wound healing. Staff involved in playing the music will also complete a short questionnaire about their observations of the wound care experience. Photos of wounds that are already taken as part of usual care may be reviewed to look at healing over time.\n\nParticipants may take part in the study for up to six months or until their wound has healed. Taking part is voluntary, and participants or their decision-makers can choose to stop at any time. The study does not change the medical care participants receive.",[664,665,666],"Pressure Injuries","Pressure Injury","Pressure Ulcer (PU)",[668,665,669,670,671,672,673],"Pressure Ulcer","Music","Wound Care","Long-Term Care","Aged","Quality of Life","2026-03-03",{"date":676,"type":41},"2026-03-06",{"date":601,"type":22},{"date":679,"type":22},"2027-06-01",{"name":47,"class":48},11,{"id":683,"slug":684,"hasResults":12,"nctId":685,"briefTitle":686,"officialTitle":687,"acronym":688,"eligibilityCriteria":689,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":449,"enrollmentInfo":690,"targetDuration":4,"studyType":23,"phases":692,"briefSummary":694,"conditions":695,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":698,"lastUpdatePostDateStruct":699,"startDateStruct":700,"completionDateStruct":702,"leadSponsor":703,"locationsCount":79},"100474115","phase-1-intravenous-dnase-i-for-the-treatment-of-sepsis-idealsepsisi-100474115","NCT05453695","Intravenous DNase I for the Treatment of Sepsis (IDEALSepsisI)","Intravenous DNase I for the Treatment of Sepsis: A Phase I Safety and Feasibility Study in ICU Patients","IDEALSepsisI","Inclusion Criteria:\n\n1. Age of ≥18 years\n2. Admitted to the ICU in the last 48 hours\n3. Suspected or proven infection as the admitting diagnosis\n4. A sequential (sepsis) organ function assessment (SOFA) score of ≥2 above baseline\n5. Expected to remain in the ICU for ≥ 72 hours\n\nExclusion Criteria:\n\n1. No consent\u002Finability to obtain consent from a substitute decision-maker\n2. Have other forms of clinically apparent shock, including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponade, tension pneumothorax), hemorrhagic, neurogenic, or anaphylactic shock\n3. Have a significant risk of bleeding as evidenced by one of the following:\n\n   * Surgery requiring general or spinal anesthesia within 24 hours before enrolment\n   * The potential need for surgery in the next 24 hours\n   * Evidence of active bleeding\n   * A history of severe head trauma requiring hospitalization\n   * Intracranial surgery, or stroke within three months before the study\n   * Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or mass lesions of the central nervous system\n   * A history of congenital bleeding diatheses\n   * Gastrointestinal bleeding within five weeks before the study unless corrective surgery had been performed\n   * Trauma is considered to increase the risk of bleeding\n   * Presence of an epidural catheter\n   * Need for therapeutic anticoagulation\n4. Receiving DNase I by inhalation\n5. Terminal illness with a life expectancy of fewer than three months\n6. Pregnant and\u002For breastfeeding",{"count":691,"type":22},36,[693],"PHASE1","Phase I dose-escalation safety and feasibility of IV DNase I in ICU septic patients.",[696,697],"Sepsis","Critical Illness","2026-03-02",{"date":674,"type":41},{"date":701,"type":41},"2023-01-17",{"date":43,"type":22},{"name":47,"class":48},{"id":705,"slug":706,"hasResults":12,"nctId":707,"briefTitle":708,"officialTitle":709,"acronym":4,"eligibilityCriteria":710,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":711,"targetDuration":4,"studyType":23,"phases":712,"briefSummary":713,"conditions":714,"keywords":717,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":722,"lastUpdatePostDateStruct":723,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":728,"locationsCount":4},"100624858","written-sepsis-education-for-patients-100624858","NCT07415096","Written Sepsis Education for Patients","Setting Up For Success: A Pilot Feasibility Randomized Controlled Trial of Written Education for Sepsis Survivors","Inclusion Criteria:\n\n* Confirmed diagnosis of sepsis based on the sepsis-3 definition (infection + Sequential Organ Failure Assessment \\[SOFA\\] increase \\>2)\n* Admitted to an ICU\n* At least 18 years old at study commencement\n\nExclusion Criteria:\n\n* Unable to read basic English\n* Despite available accommodations, they lack the cognitive, mental, or physical capacity to complete study assessments by ICU discharge\n* Readmitted to ICU during their index hospital stay\n* Hospital length of stay surpasses 30 days.",{"count":333,"type":22},[61],"This pilot feasibility randomized controlled trial (RCT) aims to determine if it feasible to recruit, deliver, and evaluate a written discharge educational material (a brochure) to adult Intensive Care Unit (ICU) patients diagnosed with sepsis.\n\nThe main questions it aims to answer are:\n\n1. Feasibility to identify and enroll \\>80% of eligible participants\n2. Feasibility to recruit 30 participants over a 6-month period\n3. Fidelity of intervention, assessed as \\>75% of participants receiving assigned intervention Researchers will assess the feasibility of comparing two groups: (1) Control - usual ICU discharge care, and (2) Intervention - usual ICU discharge care plus the receipt of an educational sepsis brochure and an explicit opportunity to ask questions about sepsis, answered by a trained intensive care unit (ICU) Registered Nurse.\n\nParticipants will receive intervention or control just prior to their discharge from ICU. They will complete online or phone survey assessments 24-48 hours post ICU discharge and 15-days post hospital discharge. Mortality and readmission data will additionally be assessed at 30-days post-discharge.",[696,715,716],"Sepsis and Septic Shock","Sepsis at Intensive Care Unit",[696,718,719,720,721],"Post-Sepsis Syndrome","Patient Education","Sepsis Rehabilitation","Care Transitions","2026-03-01",{"date":674,"type":41},{"date":725,"type":22},"2026-02",{"date":727,"type":22},"2026-09",{"name":47,"class":48},""]